Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Genome-Wide CRISPR-Cas9 Screening to Uncover Mechanisms of Novel Therapeutics Targeting Cancer Stem Cells
FY 2022-23
Summary
It is estimated that 2 in 5 Canadians will be diagnosed with cancer in their lifetime, with 1 in 4 ultimately dying from the disease. Despite recent advances in therapeutic development, treatment of complex cancers such as acute myeloid leukemia (AML) remains challenging, with an overall five-year survival of just 24%. This is largely due to high rates of disease relapse, which may be attributed to the survival of a rare subset of cells within a tumor which are genetically distinct from the rest. Known as cancer stem cells (CSCs), these cells survive even after chemotherapeutic treatment and allow for regrowth of tumors, resulting in patient relapse. CSCs have been identified in a variety of cancers including AML, brain cancer, colon cancer and breast cancer. Therefore, to consistently achieve lasting remission and improve patient outcomes, current drug development methodologies must be adapted such that they can target CSCs while minimizing their impact on healthy stem cells.
Through understanding the genetic differences between CSCs and their healthy counterparts, we will be able to selectively target and kill these cells alone. Over the past decade, our research program has developed and refined a method of identifying novel chemical compounds for their ability to kill CSCs while leaving healthy cells unharmed. We now aim to uncover the genetic workings of these compounds and assess their ability to be used as alternatives or supplements to current chemotherapeutics. Therefore, my project aims to assess the mechanism of action of these identified novel compounds to further refine these drug candidates towards approval in clinical patient testing
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486243
Name
Shull Caylie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Genome-Wide CRISPR-Cas9 Screening to Uncover Mechanisms of Novel Therapeutics Targeting Cancer Stem Cells
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biology; Cancer; Crispr/Cas9; Drug Development; Hematology; Relapse; Stem Cells
Abstract
It is estimated that 2 in 5 Canadians will be diagnosed with cancer in their lifetime, with 1 in 4 ultimately dying from the disease. Despite recent advances in therapeutic development, treatment of complex cancers such as acute myeloid leukemia (AML) remains challenging, with an overall five-year survival of just 24%. This is largely due to high rates of disease relapse, which may be attributed to the survival of a rare subset of cells within a tumor which are genetically distinct from the rest. Known as cancer stem cells (CSCs), these cells survive even after chemotherapeutic treatment and allow for regrowth of tumors, resulting in patient relapse. CSCs have been identified in a variety of cancers including AML, brain cancer, colon cancer and breast cancer. Therefore, to consistently achieve lasting remission and improve patient outcomes, current drug development methodologies must be adapted such that they can target CSCs while minimizing their impact on healthy stem cells.
Through understanding the genetic differences between CSCs and their healthy counterparts, we will be able to selectively target and kill these cells alone. Over the past decade, our research program has developed and refined a method of identifying novel chemical compounds for their ability to kill CSCs while leaving healthy cells unharmed. We now aim to uncover the genetic workings of these compounds and assess their ability to be used as alternatives or supplements to current chemotherapeutics. Therefore, my project aims to assess the mechanism of action of these identified novel compounds to further refine these drug candidates towards approval in clinical patient testing
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shull, Caylie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~